A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515)
This research is being done to find out if the medication called durvalumab will work and be safe for the treatment of patients with Stage I/II Non Small Cell Lung Cancer following stereotactic body radiation therapy.
Non Small Cell Lung Cancer stage I/II
Stage I to II Non Small Cell Lung Caner, and planned to receive definitive treatment with SBRT (Stereotactic Body Radiation Therapy)
18 - 120
Healthy Volunteers Needed
Duration of Participation
Patients will receive their assigned treatment for up to 24 months and follow up for up to 72 months.
OHSU Knight Cancer Institute